Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Corporate Action-Board approves Dividend

 Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held on 16.05.2022 at 03.00 p.m. considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended 31.03.2022 along with Statement of Assets and Liabilities and cash flow statement as on that date. a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 of SEBI (LODR) Regulations, 2015. 2. The Audited Standalone Financial Statements for the Financial Year ended March 31, 2022. 3. Recommended Final Dividend at 7% per Equity Share having face value of Rs. 10/- each for the Financial Year 2021-22; subject to the approval of the shareholders at the ensuing AGM of the Company; The Board Meeting commenced at 03.00 p.m. and concluded at 6:45 p.m.
16-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Financial Results For The Board Meeting Held On 16Th May, 2022

 Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held on 16.05.2022 at 03.00 p.m. considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended 31.03.2022 along with Statement of Assets and Liabilities and cash flow statement as on that date. a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 of SEBI (LODR) Regulations, 2015. 2. The Audited Standalone Financial Statements for the Financial Year ended March 31, 2022. 3. Recommended Final Dividend at 7% per Equity Share having face value of Rs. 10/- each for the Financial Year 2021-22; subject to the approval of the shareholders at the ensuing AGM of the Company; The Board Meeting commenced at 03.00 p.m. and concluded at 6:45 p.m.
16-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Held On 16Th May, 2022

 Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held on 16.05.2022 at 03.00 p.m. considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended 31.03.2022 along with Statement of Assets and Liabilities and cash flow statement as on that date. a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 of SEBI (LODR) Regulations, 2015. 2. The Audited Standalone Financial Statements for the Financial Year ended March 31, 2022. 3. Recommended Final Dividend at 7% per Equity Share having face value of Rs. 10/- each for the Financial Year 2021-22; subject to the approval of the shareholders at the ensuing AGM of the Company; The Board Meeting commenced at 03.00 p.m. and concluded at 6:45 p.m.
16-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board to consider Dividend

 Fredun Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on May 16, 2022 inter alia, to consider and approve the following:1. Audited Financial Results for the last quarter and financial year ended March 31, 2022 along with the Statement of Assets and Liabilities and Cash Flow statement as on that date.2. Audited Financial Statements for the Financial Year ended March 31, 2022.3. Recommend dividend for the Financial Year ended March 31, 2022 subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company.Further, in continuation of the intimation dated March 31, 2022 and pursuant to Company''s "Code of Conduct" formed under the Securities and Exchange Board of India (Prohibition of Insider Trading" Regulations, 2015 and amendments thereunder, the trading window for dealing in the securities of the Company has been closed from April 01, 2022 and it shall remain closed until fortyeight hours after the date of declaration of results for the quarter and year ended March 31, 2022. The same has been circulated to the Directors, Key Managerial Personnel, Employees of the Company and their immediate relatives.
09-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Notice Of Board Meeting The Company To Be Held On 16Th May, 2022

 Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2022 ,inter alia, to consider and approve Notice is hereby given pursuant to Regulation 29, 33 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the meeting of the Board of Directors of Fredun Pharmaceuticals is scheduled to be held on Monday 16th May, 2022 inter alia, to consider and approve the following: 1. Audited Financial Results for the last quarter and financial year ended March 31, 2022 along with the Statement of Assets and Liabilities and Cash Flow statement as on that date. 2. Audited Financial Statements for the Financial Year ended March 31, 2022. 3. Recommend dividend for the Financial Year ended March 31, 2022 subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company.
07-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Clarification On Price Movement

 With reference to your email ref. no L/SURV /ONL/PV /NP I 2022-2023 I 2311 dated 22nd April, 2022, seeking clarification in respect of movement in share price of the Company. In this regard, we wish to inform that the Company has made all the necessary disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and has not withheld any material information/event that in our opinion would have a bearing on the price /volume behavior in the scrip. Therefore, the movement in the price of the Company is purely due to the market conditions and absolutely market driven. The management of the company is in no way connected with the movement in the price of the shares. We request you to take note the above on your records.
27-04-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Clarification sought from Fredun Pharmaceuticals Ltd

 The Exchange has sought clarification from Fredun Pharmaceuticals Ltd on April 22, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.
23-04-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Yearly Certificate Under Regulations 40(9) Of SEBI Listing Regulations, 2015

 Dear Sir / Madam, In compliance to Regulation 40(9) of SEBI Listing Regulations, 2015; we furnish hereunder the certificate for the year ended March 31, 2022 of Fredun Pharmaceuticals Limited as issued by Ms. Kala Agarwal, Practising Company Secretary. Kindly take the same on your Records.
20-04-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Fund Raising By Issuance Of Debt Securities By Large Entities-Annual Disclosure

 Pursuant to the SEBI Circular No.: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, regarding Fund Raising by Issuance of Debt Securities by Large Entities; this is to confirm that the Company does not fall in the criteria mentioned under the said Circular and therefore does not qualify as Large Corporate as on 31st March, 2022. Kindly take the same on your records and acknowledge the receipt.
14-04-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Fund Raising By Issuance Of Debt Securities By Large Entities-Initial Disclosure

 Pursuant to the SEBI Circular No.: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, regarding Fund Raising by Issuance of Debt Securities by Large Entities; this is to confirm that the Company does not fall in the criteria mentioned under the said Circular and therefore does not qualify as Large Corporate as on 31st March, 2022. Kindly take the same on your records and acknowledge the receipt.
14-04-2022
Next Page
Close

Let's Open Free Demat Account